β-Galactosidase-activated theranostic for hepatic carcinoma therapy and imaging

Mrinmoy Maiti; Kai Kikuchi; K. K. Athul; Amandeep Kaur; Sankarprasad Bhuniya

doi:10.1039/d2cc01825j

β-Galactosidase-activated theranostic for hepatic carcinoma therapy and imaging

Mrinmoy Maiti, Kai Kikuchi, K. K. Athul, Amandeep Kaur, Sankarprasad Bhuniya

Research output: Contribution to journal › Article › Research › peer-review

2 Citations (Scopus)

Abstract

A β-galactosidase activatable fluorescent turn-on theranostic Gal-CGem exhibits gemcitabine release specifically in β-galactosidase overexpressing hepatic carcinoma cells. The cytotoxicity of Gal-CGem in cancer cells is achieved through the apoptotic cell death pathway. Overall, Gal-CGem is a new frontline prodrug in cancer therapy that has provided antineoplastic information through fluorescence imaging.

Original language	English
Pages (from-to)	6413-6416
Number of pages	4
Journal	Chemical Communications
Volume	58
Issue number	44
DOIs	https://doi.org/10.1039/d2cc01825j
Publication status	Published - 3 May 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/d2cc01825j

Cite this

@article{16b2b2f3393c41d0a5d111254bb921d5,

title = "β-Galactosidase-activated theranostic for hepatic carcinoma therapy and imaging",

abstract = "A β-galactosidase activatable fluorescent turn-on theranostic Gal-CGem exhibits gemcitabine release specifically in β-galactosidase overexpressing hepatic carcinoma cells. The cytotoxicity of Gal-CGem in cancer cells is achieved through the apoptotic cell death pathway. Overall, Gal-CGem is a new frontline prodrug in cancer therapy that has provided antineoplastic information through fluorescence imaging.",

author = "Mrinmoy Maiti and Kai Kikuchi and Athul, {K. K.} and Amandeep Kaur and Sankarprasad Bhuniya",

note = "Publisher Copyright: {\textcopyright} 2022 The Royal Society of Chemistry",

year = "2022",

month = may,

day = "3",

doi = "10.1039/d2cc01825j",

language = "English",

volume = "58",

pages = "6413--6416",

journal = "Chemical Communications",

issn = "1359-7345",

publisher = "The Royal Society of Chemistry",

number = "44",

}

TY - JOUR

T1 - β-Galactosidase-activated theranostic for hepatic carcinoma therapy and imaging

AU - Maiti, Mrinmoy

AU - Kikuchi, Kai

AU - Athul, K. K.

AU - Kaur, Amandeep

AU - Bhuniya, Sankarprasad

PY - 2022/5/3

Y1 - 2022/5/3

N2 - A β-galactosidase activatable fluorescent turn-on theranostic Gal-CGem exhibits gemcitabine release specifically in β-galactosidase overexpressing hepatic carcinoma cells. The cytotoxicity of Gal-CGem in cancer cells is achieved through the apoptotic cell death pathway. Overall, Gal-CGem is a new frontline prodrug in cancer therapy that has provided antineoplastic information through fluorescence imaging.

AB - A β-galactosidase activatable fluorescent turn-on theranostic Gal-CGem exhibits gemcitabine release specifically in β-galactosidase overexpressing hepatic carcinoma cells. The cytotoxicity of Gal-CGem in cancer cells is achieved through the apoptotic cell death pathway. Overall, Gal-CGem is a new frontline prodrug in cancer therapy that has provided antineoplastic information through fluorescence imaging.

UR - http://www.scopus.com/inward/record.url?scp=85131218882&partnerID=8YFLogxK

U2 - 10.1039/d2cc01825j

DO - 10.1039/d2cc01825j

M3 - Article

C2 - 35543438

AN - SCOPUS:85131218882

VL - 58

SP - 6413

EP - 6416

JO - Chemical Communications

JF - Chemical Communications

SN - 1359-7345

IS - 44

ER -

β-Galactosidase-activated theranostic for hepatic carcinoma therapy and imaging

Abstract

UN SDGs

Access to Document

Other files and links

Cite this